Associations of the rs1132896 polymorphism of the matrix metalloproteinase type 2 gene with the development of acute cerebrovascular accident: prospective case–control study

Cover Page

Cite item

Full Text

Abstract

BACKGROUND: The study focused on the identification of new genetic predictors in the Russian population, particularly associations of the rs1132896 polymorphism of the matrix metalloproteinase type 2 gene (MMP-2) with the development of acute cerebrovascular accident (ACVA).

OBJECTIVE: To investigate the relationship of rs1132896 gene MMP-2 polymorphisms with ACVA development.

MATERIALS AND METHODS: The prospective, case–control study enrolled 318 patients with stroke (main group) and 323 controls (control group). The age of the patients in the main group ranged from 32 to 69 [57.0; 51.0–62.0] years. In the control group, the age of the patients ranged from 37 to 68 [55.0; 51.0–62.0] years, which was comparable to that of the main group. Sexual dimorphism was as follows: 191 men (age [56.5; 51.0–62.0]) and 127 women (age [57.0; 51.0–62.0]). The sex composition in the control group corresponded to that in the main group: 214 men (age [55.0; 51.0–62.0]) and 109 women (age [55.0; 51.0–62.0]). The main group underwent clinical examination, computed tomography of the brain, electrocardiography, echocardioscopy, duplex ultrasound scanning of the extracranial brachiocephalic arteries, 24-h monitoring of blood pressure and heart rate, and analysis of the blood coagulation system. Molecular genetic research was conducted at a branch of the Institute of Cytology and Genetics of the Siberian Branch of RAS (Novosibirsk). All patients provided written informed consent to participate voluntarily in the study. The duration of the study was 3 years, starting in 2019. The primary study endpoint was a diagnosis of stroke, verification of concomitant cardiovascular pathology, and risk factors for stroke development. Statistical processing of the results was performed using SPSS Statistics v. 22 (IBM Corp., USA) and MedCalc 22.006 (Microsoft, USA). When comparing extended variables, the Mann–Whitney U-test was used. Discrete values were compared using Pearson’s χ2 test.

RESULTS: When analyzing statistical significance, a predominance of the homozygous CC genotype was recorded in the group of male patients with stroke: n=24 (12.6%) vs n=20 (9.3%; p=0.0324). In addition, in the group of women, a statistically significant predominance of the heterozygous CG genotype was noted in women with stroke: n=67 (52.8%) vs n=42 (38.5%; p=0.0420).

CONCLUSION: The homozygous CC genotype in men and the heterozygous CG genotype in women may be genetic predictors of the development of ACVA. The study of genetic factors in the development of ACVA is necessary to create a personalized approach to patient management at the outpatient and inpatient stages of medical care.

About the authors

Dmitrii A. Nikulin

Voyno-Yasenetsky Krasnoyarsk State Medical University; Federal Siberian Scientific and Clinical Center

Email: nikulin86@list.ru
SPIN-code: 7122-4397

MD, Cand. Sci. (Med.), assistant

Russian Federation, Krasnoyarsk; Krasnoyarsk

Anna A. Chernova

Voyno-Yasenetsky Krasnoyarsk State Medical University; Federal Siberian Scientific and Clinical Center

Email: anechkachernova@yandex.ru
ORCID iD: 0000-0003-2977-1792
SPIN-code: 6094-7406

MD, Dr. Sci. (Med.), Professor

Russian Federation, Krasnoyarsk; Krasnoyarsk

Svetlana Yu. Nikulina

Voyno-Yasenetsky Krasnoyarsk State Medical University

Author for correspondence.
Email: nicoulina@mail.ru
ORCID iD: 0000-0002-6968-7627
SPIN-code: 1789-3359

MD, Dr. Sci. (Med.), Professor

Russian Federation, Krasnoyarsk

Semen V. Prokopenko

Voyno-Yasenetsky Krasnoyarsk State Medical University; Federal Siberian Scientific and Clinical Center

Email: s.v.proc.58@mail.ru
ORCID iD: 0000-0002-4778-2586
SPIN-code: 1279-7072

MD, Dr. Sci. (Med.), Professor

Russian Federation, Krasnoyarsk; Krasnoyarsk

Irina I. Cherkashina

Voyno-Yasenetsky Krasnoyarsk State Medical University

Email: cherkashina@list.ru
ORCID iD: 0000-0003-3825-3946
SPIN-code: 9715-1475

MD, Dr. Sci. (Med.), Professor

Russian Federation, Krasnoyarsk

References

  1. Niu F, Wei B, Yan M, et al. Matrix metalloproteinase-2 gene polymorphisms are associated with ischemic stroke in a Hainan population. Medicine (Baltimore). 2018;97(39):e12302. doi: 10.1097/MD.0000000000012302
  2. Lucivero V, Prontera M, Mezzapesa DM, et al. Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke. Neurol Sci. 2007;28(4):165–170. doi: 10.1007/s10072-007-0814-0
  3. Galis ZS, Sukhova GK, Libby P. Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J. 1995;9(10):974–980. doi: 10.1096/fasebj.9.10.7615167
  4. Du J, Jin T, Cao Y, et al. Association between genetic polymorphisms of MMP8 and the risk of steroid-induced osteonecrosis of the femoral head in the population of northern China. Medicine (Baltimore). 2016;95(37):e4794. doi: 10.1097/MD.0000000000004794
  5. Romanic AM, White RF, Arleth AJ, et al. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke. 1998;29(5):1020–1030. doi: 10.1161/01.str.29.5.1020
  6. Clark AW, Krekoski CA, Bou SS, et al. Increased gelatinase A (MMP-2) and gelatinase-B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett. 1997;238(1–2):53–56. doi: 10.1016/s0304-3940(97)00859-8
  7. Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab. 1998;18(11):1163–1172. doi: 10.1097/00004647-199811000-00001
  8. Fatar M, Stroick M, Griebe M, Hennerici M. Matrix metalloproteinases in cerebrovascular diseases. Cerebrovasc Dis. 2005;20(3):141–151. doi: 10.1159/000087197
  9. Rosenberg GA, Navratil M. Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology. 1997;48(4):921–926. doi: 10.1212/wnl.48.4.921
  10. Vecil GG, Larsen PH, Corley SM, et al. Interleukin-1 is a key regulator of matrix metalloproteinase-9 expression in human neurons in culture and following mouse brain trauma in vivo. J Neurosci Res. 2000;61(2):212–224. doi: 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9
  11. Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia. 2005;50(4):329–339. doi: 10.1002/glia.20169
  12. Liu L, Sun J, Li G, et al. Association between MMP-12-82A/G polymorphism and cancer risk: a meta-analysis. Int J Clin Exp Med. 2015;8(8):11896–11904.
  13. Jia P, Wu N, Zhang X, Jia D. Association of matrix metalloproteinase-1-519A/G polymorphism with acute coronary syndrome: a meta-analysis. Int J Clin Exp Med. 2015;8(4):5675–5682.
  14. Zhang Y, Wang M, Zhang S. Association of MMP-9 gene polymorphisms with glaucoma: a meta-analysis. Ophthalmic Res. 2016;55(4):172–179. doi: 10.1159/000443627

Copyright (c) 2023 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies